ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
L-THP suppressed the expression of miR-93 and increased the levels of PTEN, a crucial tumor suppressor in OC.
|
31128026 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, the results of dual-luciferase reporter assays indicated that PTEN was a direct downstream target of miR-19b in OC.
|
29963131 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>miR-216a</i> up-regulation is associated with cisplatin resistance in ovarian cancer and this effect is mediated by PTEN.
|
30061175 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overall, we suggest that miR-205 functions as an oncogenic miRNA by directly binding to SMAD4 and PTEN, providing a novel target for the molecular treatment of ovarian cancer.
|
28145479 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.
|
29142608 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The OC tissues exhibited an increased expression of miR-214 and a reduced positive rate of PTEN expression compared with adjacent normal tissues. miR-214 may activate the PI3K/Akt signaling pathway by downregulating the targeted PTEN, which may promote OC cell proliferation and inhibit apoptosis.
|
29113199 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
|
26212011 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that although PTEN mutations in ovarian cancer are rare, PTEN inhibition results in therapeutic sensitization.
|
26905328 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Subcutaneously transplanted nude mice, as a model of human ovarian cancer, were used to test the effects of PTEN and KRT10 on cisplatin resistance of ovarian cancer in vivo.
|
26125866 |
2015 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN, a tumor suppressor gene, has been demonstrated to be able to reverse cisplatin-resistance in ovarian cancer cell line C13K.
|
24434152 |
2014 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrated that knockdown of miR-21 significantly increased the expression of PTEN, a known tumor suppressor in ovarian cancer.
|
21042775 |
2010 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway.
|
18199536 |
2008 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes.
|
17292821 |
2007 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We aimed to evaluate frequency of PTEN mutation, LOH and expression in ovarian tumors.
|
16793127 |
2006 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Between 2002-2005, probands from 300 US families with 4 or more cases of breast or ovarian cancer but with negative (wild-type) commercial genetic test results for BRCA1 and BRCA2 were screened by multiple DNA-based and RNA-based methods to detect genomic rearrangements in BRCA1 and BRCA2 and germline mutations of all classes in CHEK2, TP53, and PTEN.
|
16551709 |
2006 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that PTEN over-expression may represent a novel therapeutic approach for chemoresistant human ovarian cancer and that this may involve a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway.
|
16545436 |
2006 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified a frequency of molecular alterations in both independent and metastatic tumors, including microsatellite instability (uterine tumors, 50% and 67%, respectively; ovarian tumors, 33% and 67%) and PTEN mutations (uterine tumors, 38% and 100%; ovarian tumors, 33% and 83%) that is higher than that observed in single sporadic tumors.
|
16021566 |
2005 |
ovarian neoplasm
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
This study was performed to investigate the hypermethylation status of the PTEN gene in ovarian cancer.
|
15072831 |
2004 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
It is for the purpose of this study to investigate its function and the mechanisms by which PTEN enhances the sensitivity of ovarian cancer to antitumor agents.
|
12006545 |
2002 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN, a tumor suppressor commonly mutated (50%) in endometrial carcinoma, is found mutated in endometrioid carcinoma of the ovary, but not in other forms of ovarian cancer.
|
11949955 |
2002 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations were detected not only in the endometrioid type but also in the serous and mucinous types of ovarian cancer.
|
10629071 |
2000 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identification of frequent somatic PTEN mutations in endometrioid ovarian tumors indicates that it plays a significant role in the etiology of this subtype.
|
9605750 |
1998 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer.
|
9625810 |
1998 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations were not detected in 13 families at high risk of breast and/or ovarian cancer.
|
9399897 |
1997 |